Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO

Rank in Stocks #15555
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Share Price
$2.87
Last synced: 2026-11-13
Market Cap
$245.75M
Change (1 day)
-1.37%
Change (1 year)
-68.32%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Lexeo Therapeutics, Inc. Common Stock (LXEO)

Category

Healthcare
Operating Margin for Lexeo Therapeutics, Inc. Common Stock (LXEO)
Operating Margin as of November 2026 TTM: 0.00%
According to Lexeo Therapeutics, Inc. Common Stock's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Lexeo Therapeutics, Inc. Common Stock from 2020 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% -100.00%
2022 -9,252.14% 202.76%
2021 -3,055.94% 245.36%
2020 -884.86% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -
US
33.87% -
US
-116.04% -
US
25.57% -
AU
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Lexeo Therapeutics, Inc. Common Stock's operating margin

What was Lexeo Therapeutics, Inc. Common Stock's operating margin in 2025?

In 2025, Lexeo Therapeutics, Inc. Common Stock's operating margin was 0.00%, compared with 0.00% in 2024.

How has Lexeo Therapeutics, Inc. Common Stock's operating margin changed since 2020?

From 2020 to 2025, Lexeo Therapeutics, Inc. Common Stock's operating margin was highest in 2025 (0.00%) and lowest in 2022 (-9,252.14%).

How does Lexeo Therapeutics, Inc. Common Stock's operating margin compare with similar companies?

Lexeo Therapeutics, Inc. Common Stock's operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.